|
CBX3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63491442606301E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.73905334577285E-12 |
| Normal-vs-Stage2 |
1.027770E-01 |
| Normal-vs-Stage3 |
2.29710028776253E-10 |
| Normal-vs-Stage4 |
5.42720000051844E-08 |
| Stage1-vs-Stage2 |
7.459400E-03 |
| Stage1-vs-Stage3 |
9.874600E-01 |
| Stage1-vs-Stage4 |
4.436800E-01 |
| Stage2-vs-Stage3 |
9.115100E-03 |
| Stage2-vs-Stage4 |
6.717100E-03 |
| Stage3-vs-Stage4 |
4.470000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.33066907387547E-16 |
| Normal-vs-AfricanAmerican |
1.995130E-03 |
| Normal-vs-Asian |
5.956499999904E-07 |
| Caucasian-vs-AfricanAmerican |
6.209800E-01 |
| Caucasian-vs-Asian |
8.222600E-01 |
| AfricanAmerican-vs-Asian |
5.621400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.78339998324617E-09 |
| Normal-vs-Female |
1.6574519534629E-12 |
| Male-vs-Female |
6.448800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.36033415035308E-13 |
| Normal-vs-Age(41-60Yrs) |
3.72449848740075E-11 |
| Normal-vs-Age(61-80Yrs) |
1.197300E-04 |
| Normal-vs-Age(81-100Yrs) |
1.63529999996914E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.253800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.926300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.873000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.985650E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.120600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.353400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.501800E-01 |
| Classical-VS-Follicular |
<1E-12 |
| Classical-VS-Other |
8.897600E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
7.19949999616887E-08 |
| Tall-VS-Other |
9.191800E-01 |
| Tall-VS-Normal |
2.10780000120536E-08 |
| Follicular-VS-Other |
7.543300E-03 |
| Follicular-VS-Normal |
7.064800E-01 |
| Other-VS-Normal |
8.344000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.77499999998165E-06 |
| Normal-vs-N1 |
6.43149999923764E-08 |
| N0-vs-N1 |
1.005710E-02 |
|
|
